Microparticles, Vector of Genetic Information During HIV Infection

Public Assistance-Hospitals of Marseille (AP-HM)

Status: Completed

Conditions: HIV,

Treatments: Biological: Blood samples

Study type: Interventional

Funder types: Other

Identifiers

NCT01687452

2010-25 (Other Identifier)

2011-A00015-36

Details and patient eligibility

About

The aim of the investigators study is to demonstrate in healthy subjects and a cohort of patients infected with HIV, the presence of miRNAs in circulating peripheral blood microparticles (MPs).

Enrollment: 15 patients

Sex: Male

Ages: 30 to 50 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Age of 40 +/-10 years
• Seronegativity for the HIV 2
• Patients of the group A: seropositivity for the HIV 1 confirmed in ELISA and Western Blot for at least 2 years and having never received from antiretroviral treatment, with a viral plasmatique load > 1000 copies / ml
• Patients of the group B: seropositivity for the HIV 1 confirmed in ELISA and Western Blot for at least 2 years and under stable antiretroviral treatment for at least 6 months, with a viral load undetectable plasmatique (< 40 copies / ml)
• patients of the group C : Matching on the age (+/-3 years) to a patient
• Be considered healthy by the Investigator after a clinical examination Seronegativity for the HIV 1 confirmed in ELISA the day of the taking

Exclusion criteria

group A et B

• Age of < 30 years and > in 50 years
• Seropositivity for the HIV 2

group C Seropositivity for the HIV 2

• Be under medicinal treatment

Trial design

Primary purpose: Diagnostic

Allocation: Non-Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

15 participants in 3 patient groups, including a placebo group

Groupe A

Experimental group

Description:

Infected by the HIV Innocents of antiretroviral treatment, with a viral plasmatique load \> 1000 copies / ml

Treatment:

Biological: Blood samples

group B

Experimental group

Description:

Infected by the HIV whith antiretroviral treatment for at least 6 months,, with a viral plasmatique load \> 40 copies / ml

Treatment:

Biological: Blood samples

group C

Placebo Comparator group

Description:

Healthy volunteers

Treatment:

Biological: Blood samples